* Program subject to change
Track: Real World Data & Information Systems
PREREQUISITE: Students are expected to be familiar with relevant concepts and methodologies for analyzing real-world data, but this course does not require specific programming skills.
Jeremy Rassen, ScD
Aetion, Inc., New York, NY, USA
Sebastian Schneeweiss, MD, ScD
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Track: Study Approaches
Benjamin M. Craig, PhD
University of South Florida, Tampa, FL, USA
Bradley Martin, PharmD, RPh, PhD
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Track: Health Policy & Regulatory
PREREQUISITE: Attendance at this course or equivalent knowledge is a prerequisite to attending the course "Case Studies in Pharmaceutical/Biotech Pricing II" at ISPOR 2023.
Jack M. Mycka
MME, an Indegene PRMA Business, Montclair, NJ, USA
Track: Methodological & Statistical Research
In this short course, participants will learn how to use R to develop a number of different types of economic models to perform cost-effectiveness analysis. Economic models will include time-homogeneous and time-inhomogeneous Markov cohort models, partitioned survival models, and semi-Markov individual patient simulations. The underlying assumptions of each model type will be summarized and the implementation in R will be presented in an accessible manner. Participants will be asked to modify the models in R (eg, adding health states, use of alternative time-to-event distributions) and run analyses (eg, cost-effectiveness analysis, probabilistic sensitivity analysis, evaluating structural uncertainty, and value of information analysis). To make this interactive aspect of the course as efficient as possible, all participants will have access to the GitHub repository prior to the course. It will contain R code to run the economic models and R Markdown files to explain and reproduce the analyses covered in the course.
Devin Incerti, PhD
EntityRisk, Inc., San Francisco, CA, USA
Jeroen Jansen, PhD
PRECISIONheor and University of California, San Francisco, CA, USA
Track: Health Technology Assessment
There will be in-depth discussion of how measuring some aspects of the value of health benefits could augment the standard cost-per-quality-adjusted-life-year metric for CEA. Elements such as value of insurance, value of “hope,” real option value, severity of illness, and several others, have the potential to better capture how patients and/or society value the benefits of some treatments; each one is based on some research findings and some case examples will be shown.
The course will then review how budget considerations, cost-effectiveness thresholds, and opportunity costs enter CEA-based decision-making. Next faculty will review broader approaches to cost-benefit aggregation and value-based decision-making, including extended CEA, augmented CEA (introduced by this Report), and multi-criteria decision analysis (MCDA), with an overview of issues and new approaches to MCDA. It then discusses the strengths and weaknesses of recent US value assessment frameworks from this health economic perspective and closes with a review of the high-level recommendations of this Special Task Force.
Lou Garrison, PhD
CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA
Charles Phelps, MBA, PhD
University of Rochester, Rochester, NY, USA
Richard Willke, PhD
ISPOR, Lawrenceville, NJ, USA
Meghan Hufstader Gabriel, PhD
RTI Health Solutions, Research Triangle Park, NC, USA
Anna Hundt Golden, PhD
Mark Price, MS
PREREQUISITES: To get the most out of the course, students should have a basic statistical background. Participants who wish to gain hands-on experience are required to bring their laptops with Radiant (https://radiant-rstats.github.io/docs/install.html) installed.
Wei-Hsuan Lo-Ciganic, PhD, MSPharm, MS
University of Florida, Gainesville, FL, USA
William Padula, PhD, MSc, MS
University of Southern California, Los Angeles, CA, USA
John D. Seeger, PharmD, DrPH
Optum, Boston, MA, USA
Track: Patient-Centered Research
This is an entry level course which assumes only a passing familiarity with patient-reported outcomes.
Christina K Zigler, PhD, MSEd
Duke University School of Medicine, Durham, NC, USA
Track: Economic Evaluation
This course is suitable for those with little or no experience with health economics.
Lorne E. Basskin, PharmD
Strategic Economics Ltd., Cary, NC, USA
This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.
PREREQUISITE: Attendance at "Elements of Pharmaceutical/Biotech Pricing" at ISPOR 2023 or equivalent knowledge is a prerequisite to attending this course.
Martin Ho, MS
Biostatistician, San Francisco, CA, USA
Tommi Tervonen, PhD
Kielo Research, Zug, ZG, Switzerland
This course aims to demystify the objectives of early-stage health technology assessment and the methods of translational health economics. Students in the course will gain a thorough understanding of available methods for early-stage technology assessment, the specific challenges and solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and reimbursement. The course will utilize real-world examples and students will have the opportunity to strategize about the creation of a research plan for their purposes.
PREREQUISITE: Attendance at "Introduction to HTA" or equivalent knowledge is a prerequisite to attending this course.
William Canestaro, PhD, MSc
Washington Research Foundation, Seattle, WA, USA
Erik Landaas, PhD, MPH
Cook Medical, Ponte Vedra, FL, USA
Lotte Steuten, PhD
Office of Health Economics, London, United Kingdom
Participants who wish to gain hands-on experience must bring their laptops with Microsoft Excel for Windows installed.
Josh J. Carlson, MPH, PhD
University of Washington, Seattle, WA, USA
Adrian Towse, MA, MPhil
This course requires at least a basic knowledge of meta-analysis and statistics.
Sarah Goring, MSc
SMG Outcomes Research, Vancouver, BC, Canada
PREREQUISITE: Attendance at "Pharmacoeconomic Modeling-Applications" (6-7 June) or equivalent knowledge is a prerequisite to attending this course.
Andrew Briggs, DPhil
Avalon Health Economics, Morristown, NJ, USA
Elisabeth Fenwick, PhD
OPEN Health Evidence & Access, Oxford, OXF, United Kingdom